-
公开(公告)号：US20240360150A1
公开(公告)日：2024-10-31
申请号：US18683619
申请日：2022-08-22
发明人： Liqiang FU , Linglong KONG , Lei ZHANG , Gang LU , Yifeng XIA , Chin-Chun LU , Christine SURKA
IPC分类号： C07D498/04 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/5383 , C07D401/04 , C07D401/14 , C07D491/107 , C07D498/14
CPC分类号： C07D498/04 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/5383 , C07D401/04 , C07D401/14 , C07D491/107 , C07D498/14
摘要： An isoindolinone compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of proliferative diseases. A pharmaceutical composition contains the compound or the salt thereof and a pharmaceutically acceptable carrier.
-
2.发明公开公开(公告)号：US20240360091A1
公开(公告)日：2024-10-31
申请号：US18688300
申请日：2022-09-02
申请人： Emory University , Neurop, Inc.
发明人： Dennis Liotta , Stephen Traynelis , Lawrence Wilson , Yesim Altas Tahirovic , David Menaldino , Scott Myers , Kamalesh Poornachary
IPC分类号： C07D295/135 , A61K31/495 , A61K31/496 , C07D209/34 , C07D215/22 , C07D295/096
CPC分类号： C07D295/135 , A61K31/495 , A61K31/496 , C07D209/34 , C07D215/22 , C07D295/096
摘要： Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NMDARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and/or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.
-
公开(公告)号：US20240358709A1
公开(公告)日：2024-10-31
申请号：US18687660
申请日：2022-08-30
IPC分类号： A61K31/5375 , A61F5/56 , A61K31/138 , A61K31/216 , A61K31/437 , A61K31/496 , A61P11/04
CPC分类号： A61K31/5375 , A61F5/566 , A61K31/138 , A61K31/216 , A61K31/437 , A61K31/496 , A61P11/04
摘要： Methods of treating pharyngeal airway collapse (e.g., sleep apnea) by administering a norepinephrine reuptake inhibitor (NRI) in combination with mandibular advancement device (MAD) therapy are described herein. The treatment may further comprise administration of a muscarinic receptor antagonist (MRA) and/or a hypnotic.
-
公开(公告)号：US20240350483A1
公开(公告)日：2024-10-24
申请号：US18633291
申请日：2024-04-11
发明人： Sandeep Gaonkar , Kara Moutvic , Paul Sudhakar , Scott Boyer
IPC分类号： A61K31/496 , A61K9/20 , A61K31/519
CPC分类号： A61K31/496 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K31/519
摘要： The present invention provides for a method of treating a person suffering from a psychiatric disorder that includes administration of a pharmaceutically effective amount of (i) nefazodone, or a pharmaceutically acceptable salt thereof, and (ii) risperidone. Also provided is a unit dose that includes (i) nefazodone, or a pharmaceutically acceptable salt thereof, (ii) risperidone, and (iii) one or more pharmaceutically acceptable excipients. Also provided is a therapeutic package that includes (a) the unit doses, (b) a finished pharmaceutical container that contains the unit doses, (c) printed indicia, and (d) optionally an outside container containing the finished pharmaceutical container and the printed indicia.
-
5.发明公开公开(公告)号：US20240343704A1
公开(公告)日：2024-10-17
申请号：US18288213
申请日：2022-05-02
发明人： Anh Chau , Methvin Isaac , Babu Joseph , Radek Laufer , Gennady Poda , Michael Prakesch , Pandiaraju Subramanian , David Uehling , Iain Watson , Brian Wilson , Tao Xin
IPC分类号： C07D401/04 , A61K31/4725 , A61K31/496 , A61K31/4995 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/695 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/113 , C07D495/04 , C07D498/04 , C07D498/10 , C07F7/08
CPC分类号： C07D401/04 , A61K31/4725 , A61K31/496 , A61K31/4995 , A61K31/517 , A61K31/519 , A61K31/53 , A61K31/5377 , A61K31/538 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/695 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/113 , C07D495/04 , C07D498/04 , C07D498/10 , C07F7/0836
摘要： The present application relates to halo-substituted heterocyclic compounds of Formula (I): or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting HPK1, such as cancer.
-
公开(公告)号：US20240342186A1
公开(公告)日：2024-10-17
申请号：US18734077
申请日：2024-06-05
发明人： Annekatrin Charlotte HEIMANN , Sandra Ruth HANDSCHUH , Christoph HOENKE , Cédrickx GODBOUT , Christian GNAMM , Patrick GROSS , Marc Alexander GRUNDL , Joerg Thomas KLEY , Christian Andreas KUTTRUFF , Dirk REINART , Raphael STUBER , Theodor THEIS
IPC分类号： A61K31/5386 , A61K31/4412 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K39/395 , A61K45/06 , A61P37/06 , C07D491/048 , C07D519/00
CPC分类号： A61K31/5386 , A61K31/4412 , A61K31/496 , A61K31/519 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61P37/06 , C07D491/048 , C07D519/00
摘要： The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,
wherein
wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1,
and prodrugs or pharmaceutically acceptable salts of these compounds
for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non-alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).-
公开(公告)号：US20240342146A1
公开(公告)日：2024-10-17
申请号：US18753671
申请日：2024-06-25
IPC分类号： A61K31/439 , A61K31/438 , A61K31/496 , A61K31/5355 , A61K31/573 , A61K31/675
CPC分类号： A61K31/439 , A61K31/438 , A61K31/496 , A61K31/5355 , A61K31/573 , A61K31/675
摘要： The disclosure relates to chemotherapy treatments and in particular, formulations for antiemetic therapy. Parenteral formulations comprising Palonosetron, NK1 receptor antagonist and a corticosteroid is provided. Also provided is a process of preparing such formulations.
-
公开(公告)号：US12118414B2
公开(公告)日：2024-10-15
申请号：US16962816
申请日：2019-01-22
申请人： BioVentures, LLC
发明人： Guangrong Zheng , Daohong Zhou , Xuan Zhang , Sajid Khan , Yonghan He , Peiyi Zhang
IPC分类号： A61K31/496 , A61K45/06 , A61P35/00 , G06J1/00 , G06N3/063 , G06N5/04 , G06N10/00 , A61N5/06 , A61N5/10
摘要： The present disclosure provides compositions and methods for selectively killing cancer cells, wherein the composition comprises a compound of Formula (I). The selective killing of cancer cells occurs with an improved potency and safety profile compared to similar compounds. In particular, the compositions and methods of the invention show reduced platelet toxicity and retained or improved toxicity in cancer cells.
-
公开(公告)号：US12115171B2
公开(公告)日：2024-10-15
申请号：US17836836
申请日：2022-06-09
IPC分类号： A61K31/58 , A61K31/337 , A61K31/4409 , A61K31/4439 , A61K31/496 , A61K31/519 , A61K31/567 , A61K31/573 , A61K31/575 , A61K45/06
CPC分类号： A61K31/58 , A61K31/337 , A61K31/4409 , A61K31/4439 , A61K31/496 , A61K31/519 , A61K31/567 , A61K31/573 , A61K31/575 , A61K45/06 , A61K31/567 , A61K2300/00 , A61K31/575 , A61K2300/00 , A61K31/4439 , A61K2300/00 , A61K31/58 , A61K2300/00 , A61K31/496 , A61K2300/00 , A61K31/519 , A61K2300/00 , A61K31/4409 , A61K2300/00
摘要： Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.
-
公开(公告)号：US20240336611A1
公开(公告)日：2024-10-10
申请号：US18547190
申请日：2022-02-23
发明人： Aleksandrs ZAVORONKOVS , Aleksandr ALIPER , Vladimir ALADINSKIY , Andrey KUKHARENKO , Luoheng QUIN , Xin CHENG
IPC分类号： C07D471/08 , A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/4375 , A61K31/438 , A61K31/4439 , A61K31/496 , A61K31/4995 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/10
CPC分类号： C07D471/08 , A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/4375 , A61K31/438 , A61K31/4439 , A61K31/496 , A61K31/4995 , C07D401/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/10
摘要： Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further described herein are pharmaceutical composition comprising these compounds and methods of using these compounds. In one aspect, disclosed herein are methods of treating a disease or condition by administering the kinases inhibitors described herein.
-
-
-
-
-
-
-
-
-
搜索结果
15784 条记录 (耗时 0.066 秒)
